Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, MD PhD, David Andorsky, MD PhD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn Kolibaba, MD, Habte A. Yimer, MD, John M. Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Daniel Dingfeng Jiang, MD PhD, John C. Pesko, PhD, Tamas Vizkelety, MD, Simon Sharmokh, MPH, PharmD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137406

Published: 2020

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Ilana Schlam, MD, Samantha Buszek*, MD, Matan R Rothschild, MD, Miguel Islas-Ohlmayer, MD, James Essell

Blood (2017) 130 (Supplement 1): 5493.

https://doi.org/10.1182/blood.V130.Suppl_1.5493.5493

Published: 2017

Journal Articles

Adequate Use of the 4T´s Score As a Primary Screening Tool for Heparin Induced Thrombocytopenia

Ilana Miriam Schlam, MD, Eithan Orlev-Shitrit, MD, Chelsea Beaton, Ping Wang, Charles Glueck, MD, Miguel Islas-Ohlmayer, MD

Blood (2016) 128 (22): 5911.

https://doi.org/10.1182/blood.V128.22.5911.5911

Published: 2016

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

Journal Articles

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Paul Shaughnessy, MD, Miguel Islas-Ohlmayer, MD, Julie Murphy, Maureen Hougham, RN, Jill MacPherson, FNP, Kurt Winkler, PharmD, Matthew Silva, PharmD, Michael Steinberg, PharmD, Jeffrey Matous, MD, Sheryl Selvey, PharmD, Michael Maris, MD, Peter A. McSweeney, MD

Blood (2009) 114 (22): 2277.

https://doi.org/10.1182/blood.V114.22.2277.2277

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Adequate Use of the 4T´s Score As a Primary Screening Tool for Heparin Induced Thrombocytopenia

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Email alerts

ASH Publications

American Society of Hematology

Update search

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Adequate Use of the 4T´s Score As a Primary Screening Tool for Heparin Induced Thrombocytopenia

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only